Overview

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

Status:
Not yet recruiting

Trial end date:
2027-11-01

Target enrollment:

Participant gender:

Summary

The phase 1b study is aimed at determining the pediatric recommended phase 2 dose (RP2D) of Infigratinib. The phase 2 study will evaluate efficacy and safety of infigratinib.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Helsinn Healthcare SA

Collaborator:

Labcorp Drug Development, Inc.

Treatments:

Infigratinib